…
Bangkok Dusit Medical Services Public Company Limited, together with its subsidiaries, operates hospitals in Thailand and internationally. It operates through two segments Hospital Operations; and Other Businesses That Support Hospital Business. The company operates hospitals under the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital, and Royal Hospital Group names; and BDMS Wellness Clinic. It also offers medical laboratory, holistic clinical wellness, accounting, technology and information, training, investment and asset management, air transportation, skin and aesthetics telemedicine, and genomic medicine services; operates hotels and pharmacies; provides health insurance and insurance brokerage services; retails medicine and pharmaceutical products; and distributes health products and cosmetic products, as well as facility management services. In addition, the company is involved in production and distribution of medicines, pharmaceutical products, medical equipment, and saline; real estate; e-commerce; and investment and operation of BDMS silver wellness and residence products. Bangkok Dusit Medical Services Public Company Limited was founded in 1969 and is headquartered in Bangkok, Thailand.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bangkok Dusit Medical Services Public Company Limited is one of Thailand's largest private hospital operators, operating a nationwide network of hospitals and clinics that deliver inpatient, outpatient and specialized care. Long-term growth may be supported by demographic aging, higher domestic healthcare spending, medical tourism and measured network and service expansion, and investors may find its scale and diversified service mix attractive.
Key risks include regulatory or reimbursement changes, execution risk from expansion, competition from other providers and sensitivity to Thai macroeconomic and public-health disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 20046.15M | 20331.30M | 18652.00M | 16481.38M | 10593.75M |
| Minority interest | -520.14M | -552.13M | -522.18M | -648.03M | -554.30M |
| Net income | 15835.28M | 15987.01M | 14375.27M | 12606.20M | 7936.08M |
| Selling general administrative | 21783.69M | 20828.11M | 19805.96M | 17654.57M | 15028.62M |
| Gross profit | 38890.68M | 39796.43M | 37440.47M | 33604.26M | 24989.39M |
| Reconciled depreciation | 6848.16M | 6131.73M | 5848.05M | 5949.63M | 6321.29M |
| Ebit | 18447.68M | 20764.69M | 19198.59M | 17105.34M | 11317.64M |
| Ebitda | 25290.09M | 26896.42M | 25046.64M | 23054.97M | 17638.93M |
| Depreciation and amortization | 6842.41M | 6131.73M | 5848.05M | 5949.63M | 6321.29M |
| Operating income | 18447.68M | 20513.90M | 18935.72M | 16991.81M | 11227.96M |
| Other operating expenses | 92968.60M | 87353.32M | 81916.85M | 74949.93M | 63227.97M |
| Interest expense | 356.27M | 433.39M | 546.59M | 632.07M | 728.46M |
| Tax provision | 3694.17M | 3792.16M | 3754.55M | 3227.15M | 2103.37M |
| Interest income | 113.39M | 174.80M | 173.47M | 79.82M | 73.14M |
| Net interest income | -243.17M | -258.58M | -373.12M | -552.24M | -655.32M |
| Income tax expense | 3691.15M | 3792.16M | 3754.55M | 3227.15M | 2103.37M |
| Total revenue | 111416.29M | 107867.22M | 100852.58M | 91933.63M | 74451.35M |
| Total operating expenses | 20442.99M | 19282.53M | 18504.75M | 16620.56M | 13766.01M |
| Cost of revenue | 72525.61M | 68070.79M | 63412.11M | 58329.38M | 49461.96M |
| Total other income expense net | 1598.47M | -182.60M | -283.72M | 49.93M | 25.69M |
| Net income from continuing ops | 16368.36M | 16539.14M | 14897.45M | 13254.23M | 8490.38M |
| Net income applicable to common shares | - | - | - | 12606.20M | 7936.08M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 157832.19M | 151514.07M | 143595.95M | 141542.86M | 128453.62M |
| Intangible assets | 2761.46M | 2273.72M | 1837.13M | 1621.18M | 1289.02M |
| Other current assets | 458.14M | 388.39M | 366.97M | 115.77M | 605.42M |
| Total liab | 47913.19M | 47587.56M | 44723.47M | 47830.07M | 40688.69M |
| Total stockholder equity | 105807.87M | 100036.58M | 95441.84M | 89879.25M | 83845.19M |
| Other current liab | 11448.75M | 10623.03M | 9326.68M | 9823.52M | 8657.21M |
| Common stock | 1587.90M | 1589.20M | 1589.20M | 1589.20M | 1589.20M |
| Capital stock | 1589.20M | 1589.20M | 1589.20M | 1589.20M | 1589.20M |
| Retained earnings | 55964.65M | 56302.90M | 51799.27M | 47774.16M | 42772.86M |
| Other liab | - | - | - | 10032.10M | 9442.41M |
| Good will | 17524.56M | 17538.87M | 17538.87M | 17538.87M | 17538.87M |
| Other assets | - | - | - | 1073.74M | 1073.40M |
| Cash | 6336.42M | 7373.00M | 7794.83M | 12668.01M | 10933.66M |
| Total current liabilities | 23609.36M | 22013.59M | 18433.33M | 20616.31M | 15862.00M |
| Current deferred revenue | 190.29M | 190.08M | 190.97M | 183.25M | 169.51M |
| Net debt | 11150.58M | 10984.90M | 10339.18M | 10925.86M | 7895.86M |
| Short term debt | 6878.94M | 4818.17M | 2817.09M | 6412.22M | 3445.24M |
| Short long term debt | 6499.82M | 4499.88M | 2499.97M | 5531.84M | 3176.29M |
| Short long term debt total | 17487.00M | 18357.90M | 18134.02M | 23593.87M | 18829.52M |
| Other stockholder equity | 30141.49M | 41968.67M | 41877.55M | 40340.07M | 39307.31M |
| Property plant equipment | - | - | - | 91528.42M | 82551.16M |
| Total current assets | 23089.67M | 23659.49M | 23545.49M | 27799.08M | 24401.39M |
| Long term investments | 2944.96M | 2463.91M | 2093.83M | 1964.68M | 1487.93M |
| Net tangible assets | - | - | - | 70719.21M | 65017.31M |
| Short term investments | 899.57M | 1342.50M | 1700.04M | 2319.56M | 1726.63M |
| Net receivables | 11975.92M | 11952.13M | 11263.91M | 10246.49M | 8849.19M |
| Long term debt | 3000.00M | 5999.46M | 7998.71M | 10497.82M | 12496.12M |
| Inventory | 3419.62M | 2603.47M | 2419.73M | 2211.28M | 2004.94M |
| Accounts payable | 5091.38M | 4937.50M | 4495.33M | 4197.32M | 3590.03M |
| Accumulated other comprehensive income | 18113.82M | 175.82M | 175.82M | 175.82M | 175.82M |
| Non currrent assets other | 932.02M | 1193.87M | 1263.58M | 1012.96M | 1104.30M |
| Non current assets total | 134742.52M | 127854.58M | 120050.46M | 113743.78M | 104052.22M |
| Capital lease obligations | 7987.18M | 7858.57M | 7635.33M | 7564.22M | 3157.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 393.55M | -11384.68M | -6033.72M | -5901.38M | -473.32M |
| Change to liabilities | - | - | - | 1204.93M | 855.12M |
| Total cashflows from investing activities | -10728.14M | -11384.68M | -7754.17M | -5901.38M | -4763.08M |
| Net borrowings | -1459.22M | -558.28M | -6867.26M | -2650.68M | -5606.02M |
| Total cash from financing activities | -13679.42M | -11969.81M | -17897.40M | -12630.65M | -18530.57M |
| Change to operating activities | - | - | - | 522.97M | 1075.25M |
| Net income | 15835.28M | 20331.30M | 18652.00M | 16481.38M | 10593.75M |
| Change in cash | -421.68M | -421.83M | -4873.18M | 1734.36M | -8732.71M |
| Begin period cash flow | 6758.10M | 7794.83M | 12668.01M | 10933.66M | 19666.37M |
| End period cash flow | 6336.42M | 7373.00M | 7794.83M | 12668.01M | 10933.66M |
| Total cash from operating activities | 23430.22M | 22957.78M | 20778.39M | 20266.38M | 14560.94M |
| Depreciation | 6842.41M | 6131.73M | 5848.05M | 5949.63M | 6321.29M |
| Other cashflows from investing activities | 0.00M | -834.41M | -643.15M | 16.58M | 22.27M |
| Dividends paid | 11906.78M | 11119.08M | 10342.94M | -7943.37M | -12737.74M |
| Change to inventory | -323.81M | -208.14M | -239.04M | -340.84M | -168.59M |
| Change to account receivables | -263.68M | -879.77M | -1242.05M | -1525.33M | -2110.86M |
| Other cashflows from financing activities | -773.45M | -292.46M | -687.19M | 1463.40M | -186.81M |
| Change to netincome | - | - | - | 1847.18M | 650.49M |
| Capital expenditures | 10407.90M | 11681.09M | 8306.63M | 5072.44M | 4370.80M |
| Change in working capital | -952.25M | -231.08M | -727.87M | -138.28M | -349.08M |
| Other non cash items | 1704.77M | -3274.17M | -2993.79M | -2026.35M | -2005.02M |
| Free cash flow | 13022.32M | 11276.69M | 12471.76M | 15193.94M | 10190.14M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BDULF Bangkok Dusit Medical Services Public Company Limited |
- -% |
0.49 | 21.38 | 20.62 | 0.10 | 3.17 | 2.74 | 11.22 |
| HCA HCA Healthcare, Inc. |
15.19 3.30% |
475.52 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-0.10 0.04% |
263.49 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.22 1.52% |
14.00 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
1.31 30.75% |
5.57 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Bangkok Dusit Medical Services Public Company Limited, together with its subsidiaries, operates hospitals in Thailand and internationally. It operates through two segments Hospital Operations; and Other Businesses That Support Hospital Business. The company operates hospitals under the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital, and Royal Hospital Group names; and BDMS Wellness Clinic. It also offers medical laboratory, holistic clinical wellness, accounting, technology and information, training, investment and asset management, air transportation, skin and aesthetics telemedicine, and genomic medicine services; operates hotels and pharmacies; provides health insurance and insurance brokerage services; retails medicine and pharmaceutical products; and distributes health products and cosmetic products, as well as facility management services. In addition, the company is involved in production and distribution of medicines, pharmaceutical products, medical equipment, and saline; real estate; e-commerce; and investment and operation of BDMS silver wellness and residence products. Bangkok Dusit Medical Services Public Company Limited was founded in 1969 and is headquartered in Bangkok, Thailand.
| Name | Title | Year Born |
|---|---|---|
| Ms. Poramaporn Prasarttong-Osoth M.D. | Pres, CEO & Authorized Director | 1971 |
| Mr. Chuladej Yossundharakul | Vice Chairman | 1933 |
| Ms. Narumol Noi-Am | Sr. EVP, CFO & Authorized Director | 1958 |
| Mr. Chairat Panthuraamphorn M.D. | COO & Director | 1955 |
| Mr. Sripop Sarasas | Chief Admin. Officer & Authorized Director | 1957 |
| Mr. Att Thongtang | Director & CEO of Group 5 | 1975 |
| Mr. Prasert Prasarttong-Osoth M.D. | Founder & Director | 1933 |
| Mr. Trin Charumilind | Chief Medical Officer | 1951 |
| Ms. Daranee Bunchongsilp | Head of Internal Audit | 1982 |
| Ms. Kessara Wongsekate | VP & Company Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.